| On Oct. 25, Pharma Research Products (214450) declined 4.39% to 41,350 won (US$ 36.30). It had declined 19.71% through the past month. Standard deviation, the volatility index for stock price, was 1.9% over the same period of time over one month. |
Compared with its close competitors within the same industry, KOSDAQ, the monthly volatility of Pharma Research Products was not so high, the earnings rate for 1 month was also the lowest with decline of stock price. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -10.3%. As bearish stock price trend, the return-on-risk was poor, compared with its peer group. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -9.1, and thus it is hard to say that the industrial comparison performance was positive.
| Close Competitors |
Earning rate (%) |
STD (1Mo) |
Return on
Risk (1Mo) |
| 1 Mo |
3 Mo |
6 Mo |
| CJ FW(051500) |
-12.0% |
-15.8% |
-32.9% |
2.1% |
-5.6 |
| DAOU DATA(032190) |
-11.5% |
-20.6% |
-20.9% |
2.0% |
-5.7 |
| PRP(214450) |
-19.7% |
-24.3% |
-36.3% |
1.9% |
-10.3 |
| Interpark(108790) |
-18.2% |
-27.5% |
-42.0% |
1.7% |
-10.7 |
| Seobu T&D(006730) |
1.3% |
-7.5% |
-17.0% |
1.6% |
0.8 |
|
| Distribution |
-8.0% |
-7.2% |
-10.9% |
0.8% |
-10.0 |
| KOSDAQ |
-7.3% |
-7.2% |
-9.8% |
0.9% |
-9.1 |
PRP(214450): 2Q(Apr ~ June) of 2016 Earnings (reported at Aug. 17. 2016)
|
Revenue |
Operating Income |
Net Income |
| 2Q of 2016 |
120.4 T |
41.4 T |
46.6 T |
| Previous Quarter |
1.9% increase |
13.7% increase |
12.6% increase |
| YoY |
43.0% increase |
6.4% increase |
53.8% increase |
|
Institutions and Individuals buy, Foreigners sell
Institutions have been buying for the past 3 trading days and foreigners have been buying for the past 2 trading days. As a shareholding sum by investor group for the past 4 weeks, institutions have bought 7,103 shares with trending trade and individuals have bought 2,890 shares lessening its position. However, during the same period, foreigners have sold 9,993 shares.
| Cumulated shareholdings per investor group (1Mo) |
|
Total shareholdings per investor group |
 |
|
 |
| * Other Investor groups, included as "other corporations", are considered as "Individuals". |
By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.